{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T12:24:57Z","timestamp":1774355097313,"version":"3.50.1"},"reference-count":13,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"33","license":[{"start":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T00:00:00Z","timestamp":1723766400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,8,16]]},"abstract":"<jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>As one of the drugs used to treat <jats:italic toggle=\"yes\">Helicobacter pylori<\/jats:italic>, furazolidone has been reported to cause gastrointestinal reactions, allergies, dizziness, and more. However, its related drug-induced lung injury has been rarely reported. Furthermore, there have been no reports of the timing for initiating hormone therapy when a pulmonary adverse reaction occurs.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>We report 2 cases, both of them showed interlobular septal thickening and nodules on the chest computed tomography. One had more discomfort symptoms and had a higher eosinophil count than the normal range, while the other only had fever symptoms and had an eosinophil count within the normal range.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnoses:<\/jats:title>\n            <jats:p>Pulmonary adverse reaction caused by furazolidone was diagnosed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>Furazolidone was discontinued, and the person with increased eosinophils received hormone therapy, while the other person did not.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>After discontinuation of medication and treatment, the symptoms of the 2 patients gradually improved.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>This report suggests that furazolidone may cause pulmonary adverse reactions to raise clinical awareness, and for the first time indicates that hormone therapy is needed for patients whose eosinophils continue to increase after discontinuation.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000039286","type":"journal-article","created":{"date-parts":[[2024,8,17]],"date-time":"2024-08-17T00:03:11Z","timestamp":1723852991000},"page":"e39286","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Pulmonary adverse reaction caused by furazolidone: Two case reports and a literature review"],"prefix":"10.1097","volume":"103","author":[{"given":"Cong","family":"Zheng","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, Yuyao People\u2019s Hospital, Ningbo, Zhejiang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yao","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Guangde Traditional Chinese Medicine Hospital, Xuancheng, Anhui, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Center for Clinical Pharmacy, Cancer Center, Zhejiang Provincial People\u2019s Hospital (Affiliated People\u2019s Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miaomiao","family":"Zhang","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuochao","family":"Ren","sequence":"additional","affiliation":[{"name":"Department of Pulmonary and Critical Care Medicine, Geriatric Medicine Center, Zhejiang Provincial People\u2019s Hospital (Affiliated People\u2019s Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaochun","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Center for Clinical Pharmacy, Cancer Center, Zhejiang Provincial People\u2019s Hospital (Affiliated People\u2019s Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zixue","family":"Xuan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Center for Clinical Pharmacy, Cancer Center, Zhejiang Provincial People\u2019s Hospital (Affiliated People\u2019s Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Hospital of Jiaxing, Affiliated Hospital of Jiaxing University, Jiaxing, Zhejiang, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6111-9927","authenticated-orcid":false,"given":"Xiuli","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Center for Clinical Pharmacy, Cancer Center, Zhejiang Provincial People\u2019s Hospital (Affiliated People\u2019s Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250503","first-page":"745","article-title":"2022 Chinese national clinical practice guideline on Helicobacter pylori eradication treatment.","volume":"42","year":"2022","journal-title":"Chin J Dig"},{"key":"R2-20250503","first-page":"49","article-title":"Meta-analysis of antimicrobial resistance of Helicobacter pylori isolates in Chinese adults.","volume":"51","author":"Zhou","year":"2024","journal-title":"Inter J Epidemiol Infect Dis"},{"key":"R3-20250503","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/1751-2980.12271","article-title":"Susceptibility of helicobacter pylori to antibiotics in Chinese patients.","volume":"16","author":"Bai","year":"2015","journal-title":"J Dig Dis"},{"key":"R4-20250503","first-page":"47","article-title":"Epidemiology of helicobacter pylori resistance.","volume":"24","author":"Li","year":"2019","journal-title":"Gastroenterology"},{"key":"R5-20250503","first-page":"397","article-title":"Guidelines for the diagnosis and treatment of Helicobacter pylori infection at the grassroots level (2019).","volume":"19","year":"2020","journal-title":"Chin J Gen Pract"},{"key":"R6-20250503","first-page":"988","article-title":"Comparison and analysis of the correlation evaluation methods for adverse drug reactions in China and the Knoop assessment scale method.","volume":"34","author":"Chen","year":"2020","journal-title":"Chin Pharm Affairs"},{"key":"R7-20250503","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.resinv.2013.09.001","article-title":"Consensus statement for the diagnosis and treatment of drug-induced lung injuries.","volume":"51","author":"Kuboa","year":"2013","journal-title":"Respir Investig"},{"key":"R8-20250503","first-page":"823","article-title":"Acute pulmonary hypersensitivity to furazolidone.","volume":"105","author":"Cortez","year":"1972","journal-title":"Am Rev Respir Dis"},{"key":"R9-20250503","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1136\/pgmj.49.573.518","article-title":"Pulmonary reaction to furoxone.","volume":"49","author":"Collins","year":"1973","journal-title":"Postgrad Med J"},{"key":"R10-20250503","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1345\/aph.1E080","article-title":"Furazolidone-induced pulmonary hypersensitivity.","volume":"39","author":"Kowalski","year":"2005","journal-title":"Ann Pharmacother"},{"key":"R11-20250503","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.12998\/wjcc.v11.i12.2832","article-title":"Furazolidone-induced pulmonary toxicity in Helicobacter pylori infection: two case reports.","volume":"11","author":"Ye","year":"2023","journal-title":"World J Clin Cases"},{"key":"R12-20250503","first-page":"1","article-title":"Consider nitrofurantoin as a cause of lung injury.","volume":"6","author":"Almeida","year":"2019","journal-title":"Eur J Case Rep Intern Med"},{"key":"R13-20250503","doi-asserted-by":"crossref","first-page":"BJGPO.2021.0083","DOI":"10.3399\/BJGPO.2021.0083","article-title":"Long-term nitrofurantoin: an analysis of complication awareness, monitoring, and pulmonary injury cases.","volume":"5","author":"Speirs","year":"2021","journal-title":"BJGP Open"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000039286","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T23:03:16Z","timestamp":1746313396000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000039286"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,16]]},"references-count":13,"journal-issue":{"issue":"33","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000039286","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,16]]}}}